{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:27Z","timestamp":1790419167628,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.03026","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T07:04:14Z","timestamp":1544079854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil"],"prefix":"10.3389","volume":"9","author":[{"given":"Emi","family":"Takashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shirakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses.","volume":"7","author":"Abed","year":"2011","journal-title":"PLoS Pathog."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/JVI.02681-13","article-title":"Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.","volume":"88","author":"Abed","year":"2014","journal-title":"J. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/AAC.44.1.78-87.2000","article-title":"Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.","volume":"44","author":"Barnett","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1128\/JVI.07242-12","article-title":"Enhanced mammalian transmissibility of seasonal influenza A\/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.","volume":"86","author":"Bouvier","year":"2012","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004065","article-title":"Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.","volume":"10","author":"Butler","year":"2014","journal-title":"PLoS Pathog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents.","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00430","DOI":"10.1128\/mBio.00430-18","article-title":"Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors.","volume":"9","author":"Jones","year":"2018","journal-title":"mBio"},{"key":"B9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial.","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422x-3-63","article-title":"New low-viscosity overlay medium for viral plaque assays.","volume":"3","author":"Matrosovich","year":"2006","journal-title":"Virol. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9148","article-title":"Development of high-yield influenza A virus vaccine viruses.","volume":"6","author":"Ping","year":"2015","journal-title":"Nat. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3851\/IMP1804","article-title":"Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.","volume":"16","author":"Rameix-Welti","year":"2011","journal-title":"Antivir. Ther."},{"key":"B15","article-title":"\u201cGenotypic and phenotypic monitoring of treatment-emergent resistance to S-033188, an influenza cap-dependent endonuclease inhibitor, in a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza,\u201d","author":"Shishido","year":"2017","journal-title":"Proceeding of the 5th ISIRV Antiviral Group Conference"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1073\/pnas.1519772113","article-title":"Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor.","volume":"113","author":"Song","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1128\/JVI.00832-13","article-title":"Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease.","volume":"87","author":"Stevaert","year":"2013","journal-title":"J. Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.","volume":"132","author":"Takashita","year":"2016","journal-title":"Antiviral Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antiviral Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R","article-title":"Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors.","volume":"10","author":"Tisdale","year":"2000","journal-title":"Rev. Med. Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","article-title":"ViroSpot microneutralization assay for antigenic characterization of human influenza viruses.","volume":"35","author":"van Baalen","year":"2017","journal-title":"Vaccine"},{"key":"B22","first-page":"369","article-title":"Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012.","volume":"87","year":"2012","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.03026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T07:04:16Z","timestamp":1544079856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.03026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":22,"alternative-id":["10.3389\/fmicb.2018.03026"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.03026","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"article-number":"3026"}}